Myeloid Malignancies
Conditions
Interventions
Intervention group:1. Venetoclax: Administered orally at 400 mg/day for 5 days, from day -7 to day -3.
2. Decitabine (Dec): Administered by intravenous infusion at 20 mg/m^2/day for 5 days, from day -
Sponsors
Xiangya hospital central south university
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosed with a myeloid malignancy (according to the WHO 2022 criteria); 2. Aged 18 to 70 years, inclusive; 3. Predicted to be at high or very high risk, or with refractory/relapsed disease; 4. Availability of a suitable healthy hematopoietic stem cell donor; 5. ECOG performance status of <= 2; 6. Voluntarily signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Active infection not under control (e.g., bacteremia, invasive fungal infection); 2. Severe organ dysfunction (LVEF =2×ULN, ALT >=3×ULN); 3. History of prior hematopoietic stem cell transplantation (HSCT) or solid organ transplantation; 4. Pregnant or lactating women; 5. Other conditions deemed unsuitable for allo-HSCT by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to neutrophil engraftment; | — |
Secondary
| Measure | Time frame |
|---|---|
| 100-day non-relapse mortality (NRM); incidence of grade III-IV acute GVHD;Change from baseline in the Quality of Life score (EORTC QLQ-C30);Change from baseline in the Symptom Burden score (MDASI);2-year Overall Survival (OS) rate;2-year Relapse-Free Survival (RFS) rate; | — |
Countries
China
Contacts
Public ContactFu Bin
Xiangya hospital central south university
Outcome results
None listed